Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Sprint Bioscience AB's
Operating Income
for the
three
months ended in Mar. 2026 was kr-14.3 Mil. Sprint Bioscience AB's Interest Expense for the
three
months ended in Mar. 2026 was kr-0.1 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Sprint Bioscience AB's Interest Coverage or its related term are showing as below:
OSTO:SPRINT'
s Interest Coverage Range Over the Past 10 Years
Min: 15.94 Med: 5115.03 Max: No Debt
Current: 15.94
OSTO:SPRINT's Interest Coverage is ranked worse than 70.56% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs OSTO:SPRINT: 15.94
Sprint Bioscience AB (OSTO:SPRINT) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Sprint Bioscience AB Interest Coverage Related Terms
Sprint Bioscience AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OSTO:SPRINT vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Interest Coverage falls into.
Sprint Bioscience AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Sprint Bioscience AB did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sprint Bioscience AB and its competitors. Over the past decade, Sprint Bioscience AB's Interest Coverage has ranged from 15.94 to 10,000.00. According to the industry distribution chart, Sprint Bioscience AB ranks #266 out of 377 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Sprint Bioscience AB's Interest Coverage too high?
Sprint Bioscience AB's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 15.94 to a high of 10,000.00. Based on the distribution chart, Sprint Bioscience AB ranks #266 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #266 out of 377 companies for Interest Coverage. This places Sprint Bioscience AB in the lower half of its industry. The industry median Interest Coverage is 106.07. Historically, Sprint Bioscience AB's own Interest Coverage has ranged from 15.94 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
Interest Coverage: 0 (At Loss)
GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
